Zai Lab Limited (ZLAB) 10-Q9 Nov 222022 Q3 Quarterly reportFinancial data

Company Profile

Cover Page

Cover Page - shares	9 Months Ended
Cover Page - shares	Sep. 30, 2022	Nov. 03, 2022
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	001-38205
Entity Registrant Name	ZAI LAB LIMITED
Entity Incorporation, State or Country Code	E9
Entity Tax Identification Number	98-1144595
Entity Address, Address Line One	4560 Jinke Road
Entity Address, Address Line Two	Bldg. 1, Fourth Floor, Pudong
Entity Address, City or Town	Shanghai
Entity Address, Country	CN
Entity Address, Postal Zip Code	201210
City Area Code	86 21
Local Phone Number	6163 2588
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Shell Company	false
Entity Central Index Key	0001704292
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Amendment Flag	false
American Depositary Shares
Document Information [Line Items]
Title of 12(b) Security	American Depositary Shares, each representing 10 Ordinary Shares, par value $0.000006 per share
Trading Symbol	ZLAB
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		743,576,320
Ordinary Shares
Document Information [Line Items]
Title of 12(b) Security	Ordinary Shares, par value $0.000006 per share
Trading Symbol	9688
Entity Common Stock, Shares Outstanding		979,087,430

Unaudited condensed consolidate

Unaudited condensed consolidated balance sheets - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 1,119,476	$ 964,100
Short-term investments	0	445,000
Accounts receivable (net of allowance for credit loss of $8 and $11 as of September 30, 2022 and December 31, 2021, respectively)	27,736	47,474
Notes receivable	10,251	7,335
Inventories, net	29,131	18,951
Value added tax recoverable - current	1,080	0
Prepayments and other current assets	22,157	18,021
Total current assets	1,209,831	1,500,881
Restricted cash, non-current	803	803
Long term investments (including the fair value measured investment of $3,316 and $15,383 as of September 30, 2022 and December 31, 2021, respectively)	3,316	15,605
Prepayments for equipment	4,068	989
Property and equipment, net	50,528	43,102
Operating lease right-of-use assets	20,269	14,189
Land use rights, net	6,824	7,811
Intangible assets, net	1,540	1,848
Long-term deposits	1,329	870
Value added tax recoverable	6	23,858
Total assets	1,298,514	1,609,956
Current liabilities:
Accounts payable	90,112	126,163
Current operating lease liabilities	6,980	5,927
Other current liabilities	58,456	60,811
Total current liabilities	155,548	192,901
Deferred income	23,205	27,486
Non-current operating lease liabilities	13,892	9,613
Total liabilities	192,645	230,000
Commitments and contingencies (Note 14)
Shareholders’ equity
Ordinary shares (par value of $0.000006 per share; 5,000,000,000 shares authorized; 961,829,720 and 955,363,980 shares issued as of September 30, 2022 and December 31, 2021, respectively; 959,724,940 and 954,981,050 shares outstanding as of September 30, 2022 and December 31, 2021, respectively)	6	6
Additional paid-in capital	2,877,361	2,825,948
Accumulated deficit	(1,799,591)	(1,418,074)
Accumulated other comprehensive income (loss)	39,549	(23,645)
Treasury Stock (at cost, 2,104,780 and 382,930 shares as of September 30, 2022 and December 31, 2021, respectively)	(11,456)	(4,279)
Total shareholders’ equity	1,105,869	1,379,956
Total liabilities and shareholders’ equity	$ 1,298,514	$ 1,609,956

Unaudited condensed consolida_2

Unaudited condensed consolidated balance sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Accounts receivable, allowance for credit loss	$ 8	$ 11
Investments, fair value	$ 3,316	$ 15,383
Ordinary shares, par value (in dollars per share)	$ 0.000006	$ 0.000006
Ordinary shares, shares authorized (in shares)	5,000,000,000	5,000,000,000
Ordinary shares, shares issued (in shares)	961,829,720	955,363,980
Ordinary shares, shares outstanding (in shares)	959,724,940	954,981,050
Treasury Stock (in shares)	2,104,780	382,930

Unaudited condensed consolida_3

Unaudited condensed consolidated statements of operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenues:
Product revenue, net	$ 56,963,000	$ 43,103,000	$ 150,633,000	$ 100,141,000
Collaboration revenue	577,000	0	1,806,000	0
Total revenues	57,540,000	43,103,000	152,439,000	100,141,000
Expenses:
Cost of sales	(20,044,000)	(12,162,000)	(53,094,000)	(30,535,000)
Research and development	(99,524,000)	(55,144,000)	(219,462,000)	(401,220,000)
Selling, general, and administrative	(66,555,000)	(59,002,000)	(186,947,000)	(149,254,000)
Loss from operations	(128,583,000)	(83,205,000)	(307,064,000)	(480,868,000)
Interest income	3,872,000	713,000	5,235,000	1,171,000
Other income (expenses), net	(36,479,000)	(13,580,000)	(79,467,000)	(12,401,000)
Loss before income tax and share of loss from equity method investment	(161,190,000)	(96,072,000)	(381,296,000)	(492,098,000)
Income tax expense	0	0	0	0
Share of loss from equity method investment	0	(340,000)	(221,000)	(548,000)
Net loss	(161,190,000)	(96,412,000)	(381,517,000)	(492,646,000)
Net loss attributable to ordinary shareholders - basic	(161,190,000)	(96,412,000)	(381,517,000)	(492,646,000)
Net loss attributable to ordinary shareholders - diluted	$ (161,190,000)	$ (96,412,000)	$ (381,517,000)	$ (492,646,000)
Loss per share/ADS - basic (in dollars per share)	$ (0.17)	$ (0.10)	$ (0.40)	$ (0.53)
Loss per share/ADS - diluted (in dollars per share)	$ (0.17)	$ (0.10)	$ (0.40)	$ (0.53)
Weighted-average shares/ADSs used in calculating net loss per ordinary share/ADS - basic (in shares)	959,085,960	950,354,320	957,439,910	921,748,380
Weighted-average shares/ADSs used in calculating net loss per ordinary share/ADS - diluted (in shares)	959,085,960	950,354,320	957,439,910	921,748,380
American Depositary Shares
Expenses:
Loss per share/ADS - basic (in dollars per share)	$ (1.68)	$ (1.01)	$ (3.98)	$ (5.34)
Loss per share/ADS - diluted (in dollars per share)	$ (1.68)	$ (1.01)	$ (3.98)	$ (5.34)
Weighted-average shares/ADSs used in calculating net loss per ordinary share/ADS - basic (in shares)	95,908,596	95,035,432	95,743,991	92,174,838
Weighted-average shares/ADSs used in calculating net loss per ordinary share/ADS - diluted (in shares)	95,908,596	95,035,432	95,743,991	92,174,838

Unaudited condensed consolida_4

Unaudited condensed consolidated statements of comprehensive loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Statement of Comprehensive Income [Abstract]
Net loss	$ (161,190)	$ (96,412)	$ (381,517)	$ (492,646)
Other comprehensive income (loss), net of tax of nil:
Foreign currency translation adjustments	35,062	1,741	63,194	(600)
Comprehensive loss	$ (126,128)	$ (94,671)	$ (318,323)	$ (493,246)

Unaudited condensed consolida_5

Unaudited condensed consolidated statements of comprehensive loss (Parenthetical) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Statement of Comprehensive Income [Abstract]
Other comprehensive (loss) income, tax	$ 0	$ 0	$ 0	$ 0

Unaudited condensed consolida_6

Unaudited condensed consolidated statements of shareholders' equity - USD ($) $ in Thousands	Total	Ordinary Shares	Additional paid in capital	Accumulated deficit	Accumulated other comprehensive (loss) income	Treasury Stock
Beginning balance (in shares) at Dec. 31, 2020		878,110,260
Beginning balance at Dec. 31, 2020	$ 1,169,345	$ 5	$ 1,897,467	$ (713,603)	$ (14,524)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of ordinary shares upon vesting of restricted shares (in shares)		816,000
Issuance of ordinary shares upon vesting of restricted shares	0	$ 0	0
Exercise of shares options (in shares)		583,640
Exercise of shares options	702	$ 0	702
Issuance cost adjustment	65		65
Issuance of ordinary shares in connection with collaboration and license arrangement/ follow-on public offering, net of issuance cost (in shares)		5,681,820
Issuance of ordinary shares in connection with collaboration and license arrangement/ follow-on public offering, net of issuance cost	62,250	$ 0	62,250
Share-based compensation	7,318		7,318
Net loss	(232,910)			(232,910)
Foreign currency translation	2,900				2,900
Ending balance (in shares) at Mar. 31, 2021		885,191,720
Ending balance at Mar. 31, 2021	1,009,670	$ 5	1,967,802	(946,513)	(11,624)	$ 0
Ending balance (in shares) at Mar. 31, 2021						0
Beginning balance (in shares) at Dec. 31, 2020		878,110,260
Beginning balance at Dec. 31, 2020	1,169,345	$ 5	1,897,467	(713,603)	(14,524)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(492,646)
Foreign currency translation	(600)
Ending balance (in shares) at Sep. 30, 2021		952,735,890
Ending balance at Sep. 30, 2021	1,587,930	$ 6	2,812,830	(1,206,249)	(15,124)	$ (3,533)
Ending balance (in shares) at Sep. 30, 2021						(277,220)
Beginning balance (in shares) at Mar. 31, 2021		885,191,720
Beginning balance at Mar. 31, 2021	1,009,670	$ 5	1,967,802	(946,513)	(11,624)	$ 0
Beginning balance (in shares) at Mar. 31, 2021						0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of ordinary shares upon vesting of restricted shares (in shares)		321,000
Issuance of ordinary shares upon vesting of restricted shares	0	$ 0	0
Exercise of shares options (in shares)		4,905,170
Exercise of shares options	3,289	$ 0	3,289
Issuance of ordinary shares in connection with collaboration and license arrangement/ follow-on public offering, net of issuance cost (in shares)		57,164,000
Issuance of ordinary shares in connection with collaboration and license arrangement/ follow-on public offering, net of issuance cost	817,996	$ 1	817,995
Receipt of employees’ shares to satisfy tax withholding obligations related to share-based compensation (in shares)						(60,860)
Receipt of employees’ shares to satisfy tax withholding obligations related to share-based compensation	(924)					$ (924)
Share-based compensation	10,232		10,232
Net loss	(163,324)			(163,324)
Foreign currency translation	(5,241)				(5,241)
Ending balance (in shares) at Jun. 30, 2021		947,581,890
Ending balance at Jun. 30, 2021	1,671,698	$ 6	2,799,318	(1,109,837)	(16,865)	$ (924)
Ending balance (in shares) at Jun. 30, 2021						(60,860)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of ordinary shares upon vesting of restricted shares (in shares)		540,500
Issuance of ordinary shares upon vesting of restricted shares	0	$ 0	0
Exercise of shares options (in shares)		4,613,500
Exercise of shares options	2,916	$ 0	2,916
Issuance cost adjustment	40		40
Receipt of employees’ shares to satisfy tax withholding obligations related to share-based compensation (in shares)						(216,360)
Receipt of employees’ shares to satisfy tax withholding obligations related to share-based compensation	(2,609)					$ (2,609)
Share-based compensation	10,556		10,556
Net loss	(96,412)			(96,412)
Foreign currency translation	1,741				1,741
Ending balance (in shares) at Sep. 30, 2021		952,735,890
Ending balance at Sep. 30, 2021	$ 1,587,930	$ 6	2,812,830	(1,206,249)	(15,124)	$ (3,533)
Ending balance (in shares) at Sep. 30, 2021						(277,220)
Beginning balance (in shares) at Dec. 31, 2021	954,981,050	955,363,980
Beginning balance at Dec. 31, 2021	$ 1,379,956	$ 6	2,825,948	(1,418,074)	(23,645)	$ (4,279)
Beginning balance (in shares) at Dec. 31, 2021	(382,930)					(382,930)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of ordinary shares upon vesting of restricted shares (in shares)		514,800
Issuance of ordinary shares upon vesting of restricted shares	$ 0	$ 0	0
Exercise of shares options (in shares)		1,156,660
Exercise of shares options	297	$ 0	297
Receipt of employees’ shares to satisfy tax withholding obligations related to share-based compensation (in shares)						(15,150)
Receipt of employees’ shares to satisfy tax withholding obligations related to share-based compensation	(68)					$ (68)
Share-based compensation	12,410		12,410
Net loss	(82,394)			(82,394)
Foreign currency translation	(2,193)				(2,193)
Ending balance (in shares) at Mar. 31, 2022		957,035,440
Ending balance at Mar. 31, 2022	$ 1,308,008	$ 6	2,838,655	(1,500,468)	(25,838)	$ (4,347)
Ending balance (in shares) at Mar. 31, 2022						(398,080)
Beginning balance (in shares) at Dec. 31, 2021	954,981,050	955,363,980
Beginning balance at Dec. 31, 2021	$ 1,379,956	$ 6	2,825,948	(1,418,074)	(23,645)	$ (4,279)
Beginning balance (in shares) at Dec. 31, 2021	(382,930)					(382,930)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ (381,517)
Foreign currency translation	$ 63,194
Ending balance (in shares) at Sep. 30, 2022	959,724,940	961,829,720
Ending balance at Sep. 30, 2022	$ 1,105,869	$ 6	2,877,361	(1,799,591)	39,549	$ (11,456)
Ending balance (in shares) at Sep. 30, 2022	(2,104,780)					(2,104,780)
Beginning balance (in shares) at Mar. 31, 2022		957,035,440
Beginning balance at Mar. 31, 2022	$ 1,308,008	$ 6	2,838,655	(1,500,468)	(25,838)	$ (4,347)
Beginning balance (in shares) at Mar. 31, 2022						(398,080)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of ordinary shares upon vesting of restricted shares (in shares)		683,700
Issuance of ordinary shares upon vesting of restricted shares	0	$ 0	0
Exercise of shares options (in shares)		2,801,000
Exercise of shares options	4,322	$ 0	4,322
Receipt of employees’ shares to satisfy tax withholding obligations related to share-based compensation (in shares)						(1,627,230)
Receipt of employees’ shares to satisfy tax withholding obligations related to share-based compensation	(6,782)					$ (6,782)
Share-based compensation	14,225		14,225
Net loss	(137,933)			(137,933)
Foreign currency translation	30,325				30,325
Ending balance (in shares) at Jun. 30, 2022		960,520,140
Ending balance at Jun. 30, 2022	1,212,165	$ 6	2,857,202	(1,638,401)	4,487	$ (11,129)
Ending balance (in shares) at Jun. 30, 2022						(2,025,310)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of ordinary shares upon vesting of restricted shares (in shares)		230,250
Issuance of ordinary shares upon vesting of restricted shares	0	$ 0	0
Exercise of shares options (in shares)		1,079,330
Exercise of shares options	1,052	$ 0	1,052
Receipt of employees’ shares to satisfy tax withholding obligations related to share-based compensation (in shares)						(79,470)
Receipt of employees’ shares to satisfy tax withholding obligations related to share-based compensation	(327)					$ (327)
Share-based compensation	19,107		19,107
Net loss	(161,190)			(161,190)
Foreign currency translation	$ 35,062				35,062
Ending balance (in shares) at Sep. 30, 2022	959,724,940	961,829,720
Ending balance at Sep. 30, 2022	$ 1,105,869	$ 6	$ 2,877,361	$ (1,799,591)	$ 39,549	$ (11,456)
Ending balance (in shares) at Sep. 30, 2022	(2,104,780)					(2,104,780)

Unaudited condensed consolida_7

Unaudited condensed consolidated statements of shareholders' equity (Parenthetical) $ in Thousands	3 Months Ended
	Jun. 30, 2021 USD ($)
Statement of Stockholders' Equity [Abstract]
Issuance costs	$ 879

Unaudited condensed consolida_8

Unaudited condensed consolidated statements of cash flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Operating activities
Net loss	$ (381,517)	$ (492,646)
Adjustments to reconcile net loss to net cash used in operating activities:
Allowance for credit (gain) loss	(3)	5
Inventory write-down	480	402
Depreciation and amortization expenses	6,100	4,612
Amortization of deferred income	(2,041)	(234)
Share-based compensation	45,742	28,106
Noncash research and development expenses	0	62,250
Share of loss from equity method investment	221	548
Loss from fair value changes of equity investment with readily determinable fair value	12,067	9,930
(Gain) loss on disposal of property and equipment	(11)	12
Noncash lease expenses	5,820	4,595
Foreign currency remeasurement loss	73,052	2,838
Changes in operating assets and liabilities:
Accounts receivable	16,483	(15,858)
Notes receivable	(3,861)	0
Inventories	(13,235)	248
Prepayments and other current assets	(5,860)	(6,142)
Long-term deposits	(459)	(39)
Value added tax recoverable	21,432	(1,249)
Accounts payable	(28,850)	(11,235)
Other current liabilities	1,628	20,591
Operating lease liabilities	(6,008)	(3,834)
Deferred income	470	863
Net cash used in operating activities	(258,350)	(396,237)
Cash flows from investing activities:
Purchases of short-term investments	(260,274)	(170,000)
Proceeds from maturity of short-term investment	705,274	743,902
Purchase of property and equipment	(20,172)	(11,917)
Purchase of intangible assets	(439)	(539)
Payment for investment in equity investee	0	(30,000)
Net cash provided by investing activities	424,389	531,446
Cash flows from financing activities:
Proceeds from exercises of stock options	5,640	6,907
Proceeds from issuance of ordinary shares upon public offerings	0	818,874
Payment of public offering costs	0	(1,836)
Employee taxes paid related to net share settlement of equity awards	(7,171)	(3,467)
Net cash (used in) provided by financing activities	(1,531)	820,478
Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash	(9,132)	695
Net increase in cash, cash equivalents and restricted cash	155,376	956,382
Cash, cash equivalents and restricted cash - beginning of period	964,903	442,859
Cash, cash equivalents and restricted cash - end of period	1,120,279	1,399,241
Supplemental disclosure on non-cash investing and financing activities:
Payables for purchase of property and equipment	3,234	1,797
Payables for intangible assets	32	24
Payables for treasury stock	32	0
Receivables for stock option exercise under equity incentive plans	31	0
Right-of-use asset acquired under operating leases	12,861	0
Supplemental disclosure of cash flow information:
Cash and cash equivalents	1,119,476	1,398,498
Restricted cash, non-current	803	743
Total cash and cash equivalents and restricted cash	$ 1,120,279	$ 1,399,241

Organization and principal acti

Organization and principal activities	9 Months Ended
Organization and principal activities	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and principal activities	Organization and principal activities Zai Lab Limited was incorporated on March 28, 2013 in the Cayman Islands as an exempted company with limited liability under the Companies Law of the Cayman Islands (as amended). Zai Lab Limited and its subsidiaries (collectively referred to as the “Company”) are focused on developing and commercializing products and product candidates that address medical conditions with unmet needs, including in the areas of oncology, autoimmune disorders, infectious diseases, and neurological disorders. The Company’s principal operations and geographic markets are in Greater China. The Company has a substantial presence in Greater China and the United States.

Basis of presentation and conso

Basis of presentation and consolidation and significant accounting policies	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of presentation and consolidation and significant accounting policies	Basis of presentation and consolidation and significant accounting policies (a) Basis of presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”), and applicable rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”), regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in the Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 1, 2022 (the “2021 Annual Report”). The December 31, 2021 condensed consolidated balance sheet data included in this Quarterly Report on Form 10-Q were derived from the audited financial statements included in the 2021 Annual Report. The accompanying condensed consolidated financial statements reflect all normal recurring adjustments that are necessary to present fairly the results for the interim periods presented. Interim results are not necessarily indicative of the results for the year ending December 31, 2022. Effective as of March 30, 2022, the Company subdivided each of its issued and unissued ordinary shares into ten ordinary shares (the “Share Subdivision”). Following the Share Subdivision, the Company’s authorized share capital became $30,000 divided into 5,000,000,000 shares with a par value of $0.000006 per share. The numbers of issued and unissued ordinary shares and per share data as disclosed elsewhere in these unaudited condensed consolidated financial statements and notes thereto are presented on a basis after taking into account the effects of the Share Subdivision and have been retrospectively adjusted, where applicable. In connection with the Share Subdivision, the conversion ratio of our ADSs to ordinary shares changed from one ADS to one ordinary share to a new ratio of one ADS to ten ordinary shares (the “ADS Ratio Change”). The Share Subdivision and ADS Ratio Change did not result in any change to the number of outstanding ADSs of the Company. A reclassification has been made within the condensed consolidated statement of cash flow for the nine months ended September 30, 2021 to conform to the current period presentation. The Company reclassified $2.8 million from other current liabilities into foreign currency remeasurement loss. The net cash used in operating activities did not change as a result of the reclassification. (b) Principles of consolidation The unaudited condensed consolidated financial statements include the financial statements of the Company and its subsidiaries. All intercompany transactions and balances among the Company and its subsidiaries are eliminated upon consolidation. (c) Use of estimates The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Areas where management uses subjective judgment include, but are not limited to, estimating the useful lives of long-lived assets, estimating the current expected credit losses for financial assets, and assessing the impairment of long-lived assets, discount rate of operating lease liabilities, accrual of rebates, allocation of research and development expenses to the appropriate financial reporting period based on the progress of the research and development projects, share-based compensation expenses, recoverability of deferred tax assets, and a lack of marketability discount of the ordinary shares issued in connection with license and collaboration arrangements (Note 12). Management bases its estimates on historical experience and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from these estimates. (d) Fair value measurements As of September 30, 2022 and December 31, 2021, information about inputs into the fair value measurement of the Company’s assets that are measured at a fair value on a recurring basis in periods subsequent to their initial recognition is as follows (in thousands): Description Fair Value as of Fair Value Measurement at Reporting Date Using Quoted Prices in Active Markets for Identical Assets (Level 1) US$ Equity Investments with Readily Determinable Fair Value 3,316 3,316 Description Fair Value as of Fair Value Measurement at Reporting Date Using Quoted Prices in Active Markets for Identical Assets (Level 1) US$ Equity Investments with Readily Determinable Fair Value 15,383 15,383 The Company did not have assets or liabilities measured at fair value on a nonrecurring basis during the periods presented. Financial instruments of the Company primarily include cash, cash equivalents and restricted cash, short-term investments, accounts receivable, notes receivable, prepayments and other current assets, accounts payable, and other current liabilities. As of September 30, 2022 and December 31, 2021, the carrying values of cash and cash equivalents, short-term investments, accounts receivable, notes receivable, prepayments and other current assets, accounts payable, and other current liabilities approximated their fair values due to the short-term maturity of these instruments, and the carrying value of restricted cash approximated its fair value based on the nature of the assessment of the ability to recover these amounts. (e) Recent accounting pronouncements Adopted accounting standards In November 2021, the FASB issued ASU2021-10, Government Assistance (Topic 832) — Disclosures by Business Entities about Government Assistance. The amendments in this ASU require disclosures about transactions with a government that have been accounted for by analogizing to a grant or contribution accounting model to increase transparency about (1) the types of transactions, (2) the accounting for the transactions, and (3) the effect of the transactions on an entity’s financial statements. The amendments in this ASU are effective for all entities within their scope for financial statements issued for annual periods beginning after December 15, 2021. The Company adopted this standard as of January 1, 2022. There was no material impact on the Company’s financial position or results of operations upon the adoption. (f) Significant accounting policies For a more complete discussion of the Company’s significant accounting policies, the unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the 2021 Annual Report.

Cash and cash equivalents

Cash and cash equivalents	9 Months Ended
Cash and cash equivalents	Sep. 30, 2022
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	Cash and cash equivalents The following table presents the Company’s cash and cash equivalents as of September 30, 2022 and December 31, 2021 (in thousands): September 30, 2022 December 31, 2021 $ $ Cash at bank and in hand 818,407 663,472 Cash equivalents (i) 301,069 300,628 1,119,476 964,100 Denominated in: US$ 1,072,376 932,888 RMB (ii) 41,138 23,791 Hong Kong dollar (“HK$”) 5,035 6,674 Australian dollar (“A$”) 579 475 Taiwan dollar (“TW$”) 348 272 1,119,476 964,100 (i) Cash equivalents represent short-term and highly liquid investments in a money market fund.

Inventories, net

Inventories, net	9 Months Ended
Inventories, net	Sep. 30, 2022
Inventory Disclosure [Abstract]
Inventories, net	Inventories, net The Company’s net inventory balance of $29.1 million and $19.0 million as of September 30, 2022 and December 31, 2021, respectively, mainly consisted of finished goods purchased from Tesaro Inc., now GlaxoSmithKline (“GSK”), for distribution in Hong Kong, from NovoCure Limited (“NovoCure”) for distribution in Hong Kong and mainland China, and from Deciphera Pharmaceuticals, LLC (“Deciphera”) for distribution in Hong Kong, mainland China and Taiwan, as well as finished goods and certain raw materials for ZEJULA and NUZYRA commercialization in mainland China. The following table presents the Company’s inventories, net, as of September 30, 2022 and December 31, 2021 (in thousands): September 30, 2022 December 31, 2021 $ $ Finished goods 8,703 5,632 Raw materials 20,397 13,231 Work in Progress 31 88 Inventories, net 29,131 18,951 The Company writes down inventory for any excess or obsolete inventories or when the Company believes that the net realizable value of inventories is less than the carrying value. The Company recorded write-downs in cost of sales of $0.3 million and $0.5 million during the three and nine months ended September 30, 2022, respectively, and of $0.1 million and $0.4 million during the three and nine months ended September 30, 2021, respectively.

Property and Equipment, net

Property and Equipment, net	9 Months Ended
Property and Equipment, net	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Property and equipment, net	Property and equipment, net The following table presents the components of the Company’s property and equipment, net as of September 30, 2022 and December 31, 2021 (in thousands): September 30, 2022 December 31, 2021 $ $ Office equipment 818 836 Electronic equipment 6,744 5,036 Vehicle 198 220 Laboratory equipment 18,673 17,069 Manufacturing equipment 14,366 14,600 Leasehold improvements 10,160 10,432 Construction in progress 19,882 11,334 70,841 59,527 Less: accumulated depreciation (20,313) (16,425) Property and equipment, net 50,528 43,102 Depreciation expense was $2.1 million and $5.7 million for the three and nine months ended September 30, 2022, respectively, and $1.5 million and $4.3 million for the three and nine months ended September 30, 2021, respectively.

Revenue

Revenue	9 Months Ended
Revenue	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
Revenue	Revenue Product revenue, net The Company’s product revenue is primarily derived from the sales of ZEJULA, Optune, QINLOCK, and NUZYRA in mainland China and Hong Kong. The table below presents the Company’s net product sales for the three and nine months ended September 30, 2022 and 2021 (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 $ $ $ $ Product revenue - gross 60,446 47,555 168,095 135,490 Less: Rebate and sales return (3,483) (4,452) (17,462) (35,349) Product revenue - net 56,963 43,103 150,633 100,141 Sales rebates are offered to distributors in mainland China, and the amounts are recorded as a reduction of revenue. Estimated rebates are determined based on contracted rates, sales volumes, and level of distributor inventories. The following table presents net revenue by product for the three and nine months ended September 30, 2022 and 2021 (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 $ $ $ $ ZEJULA 39,214 28,162 102,863 64,134 Optune 10,662 10,653 35,051 27,318 QINLOCK 5,541 4,288 9,123 8,689 NUZYRA 1,546 — 3,596 — Product revenue - net 56,963 43,103 150,633 100,141 Collaboration revenue The Company’s collaboration revenue was $0.6 million and $1.8 million for the three and nine months ended September 30, 2022, respectively, and nil for the three and nine months ended September 30, 2021. This collaboration revenue was from the Company’s collaborative arrangement with Huizheng (Shanghai) Pharmaceutical Technology Co., Ltd.

Income tax

Income tax	9 Months Ended
Income tax	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Income tax	Income tax No provision for income taxes has been required to be accrued because the Company and all of its subsidiaries are in cumulative loss positions for the periods presented. The Company recorded a full valuation allowance against deferred tax assets of all its consolidated entities because all entities were in a cumulative loss position as of September 30, 2022 and December 31, 2021. No unrecognized tax benefits and related interest and penalties were recorded in the periods presented.

Other current liabilities

Other current liabilities	9 Months Ended
Other current liabilities	Sep. 30, 2022
Other Liabilities Disclosure [Abstract]
Other current liabilities	Other current liabilities The following table presents the Company’s other current liabilities as of September 30, 2022 and December 31, 2021 (in thousands): September 30, December 31, $ $ Payroll 25,208 25,685 Accrued rebate to distributors 8,843 15,001 Tax payables 10,405 8,817 Accrued professional service fee 5,927 4,319 Other (i) 4,839 4,421 Payables for purchase of property and equipment 3,234 2,568 Total 58,456 60,811

Loss per share

Loss per share	9 Months Ended
Loss per share	Sep. 30, 2022
Earnings Per Share [Abstract]
Loss per share	Loss per share The following table presents the computation of the basic and diluted net loss per share for the three and nine months ended September 30, 2022 and 2021 (in thousands, except share and per share data): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 $ $ $ $ Numerator: Net loss attributable to ordinary shareholders (161,190) (96,412) (381,517) (492,646) Denominator: Weighted average number of ordinary shares - basic and diluted 959,085,960 950,354,320 957,439,910 921,748,380 Net loss per share - basic and diluted (0.17) (0.10) (0.40) (0.53) As a result of the Company’s net loss for the three and nine months ended September 30, 2022 and 2021, share options and non-vested restricted shares outstanding in the respective periods were excluded from the calculation of diluted loss per share as their inclusion would have been anti-dilutive. September 30, September 30, Share options 90,511,530 81,801,570 Non-vested restricted shares 34,103,830 6,366,190

Related party transactions

Related party transactions	9 Months Ended
Related party transactions	Sep. 30, 2022
Related Party Transactions [Abstract]
Related party transactions	Related party transactions The Company incurred research and development expenses for product research and development services provided by MEDx (Suzhou) Translational Medicine Co., Ltd (“MEDx”), over which an immediate family member of our Chief Executive Officer and Chairperson of the Board held significant influence. The Company incurred development expenses with MEDx of an insignificant amount and $0.3 million during the three and nine months ended September 30, 2022, respectively, and $0.1 million and $0.3 million, during the three and nine months ended September 30, 2021, respectively.

Share-based compensation

Share-based compensation	9 Months Ended
Share-based compensation	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Share-based compensation	Share-based compensation In March 2015, the Board of Directors of the Company approved an Equity Incentive Plan (the “2015 Plan”), pursuant to which the Board of Directors could grant options to purchase ordinary shares to management including officers, directors, employees, and individual advisors who rendered services to the Company. In August 2017, in connection with the completion of the initial public offering (the “IPO”) of the Company, the Board of Directors approved the 2017 Equity Incentive Plan (the “2017 Plan”). All equity-based awards subsequent to the IPO would be granted under the 2017 Plan. The 2017 Plan provided for an automatic annual increase to the number of ordinary shares reserved under the 2017 Plan on each January 1st between January 1, 2018 and January 1, 2027 equal to the lesser of 4% of the number of ordinary shares outstanding as of the close of business on the immediately prior December 31st or such number as approved by the Board on or prior to such date each year. The aggregate number of shares reserved and available for issuance under the 2017 Plan as of April 1, 2022 was 75,562,170. On June 22, 2022, at the 2022 Annual General Meeting of Shareholders of the Company (the “Annual General Meeting”), the Company’s shareholders approved the 2022 Equity Incentive Plan (the “2022 Plan”), which was previously approved by the Company’s Board of Directors on April 20, 2022, conditioned on and subject to (i) the dual primary listing of the Company on the Main Board of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”) and (ii) the granting of a waiver on Note 1 to Rule 17.03(9) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The Company’s voluntary conversion of its secondary listing status to primary listing status on the Hong Kong Stock Exchange became effective on June 27, 2022, and the waiver was granted to the Company in connection with the primary conversion. As such, the 2022 Plan became effective on June 27, 2022, and the aggregate number of shares that may be delivered in satisfaction of awards under the 2022 Plan is 97,908,743 ordinary shares as of June 22, 2022. No new grants will be made under the 2015 Plan or the 2017 Plan as of the effective date of the 2022 Plan. For the nine months ended September 30, 2022, the Company granted 19,357,640 share options and 28,320,790 non-vested restricted shares to certain management and employees of the Company under the 2017 Plan. The share options were granted at an exercise price ranging from $2.95 to $6.29 per share. The share options granted were valued using the Black-Scholes model, and the weighted-average grant-date fair value was $2.84 per share. The options granted have a contractual term of ten years and generally vest ratably over a five-year period, with 20% of the awards vesting on each anniversary of the grant date. The non-vested restricted shares granted vest ratably over a five Upon each settlement date of the share awards, shares were withheld to cover the required withholding tax, which was based on the value of a share on the settlement date as determined by the closing price of the ADSs on the trading day of the applicable settlement date. The remaining shares after the withholding were delivered to the recipient. The amount remitted to the tax authorities for employee tax obligations was reflected as a financing activity on the condensed consolidated statements of cash flows. These shares withheld by the Company as a result of the net settlement were accounted for as treasury stock and not considered issued and outstanding. Stock-based compensation expense has been reported in the Company’s condensed consolidated statements of operations and comprehensive loss as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 $ $ $ $ Selling, general and administrative 11,298 6,147 27,221 16,579 Research and development 7,809 4,409 18,521 11,527 Total 19,107 10,556 45,742 28,106 As of September 30, 2022, there was unrecognized share-based compensation expense of $111.9 million related to unvested share options which the Company expects to recognize over a weighted-average period of 3.47 years. As of September 30, 2022, there was unrecognized share-based compensation expense of $143.0 million related to unvested restricted shares which the Company expects to recognize over a weighted-average period of 3.70 years.

License and collaboration arran

License and collaboration arrangements	9 Months Ended
License and collaboration arrangements	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
License and collaboration arrangements	License and collaboration arrangements The following is a description of the license and collaboration agreements for which the Company recorded expenses or made payments related to upfront or milestone fees during the three and nine months ended September 30, 2022. License and collaboration agreement with GSK In September 2016, the Company entered into a collaboration, development, and license agreement with Tesaro, Inc., a company later acquired by GSK, pursuant to which the Company obtained an exclusive sublicense under certain patents and know-how of GSK to develop, manufacture, and commercialize GSK’s proprietary PARP inhibitor, niraparib, in mainland China, Hong Kong, and Macau for the diagnosis and prevention of any human diseases or conditions (other than prostate cancer). Under the terms of the agreement, in the third quarter of 2022, the Company made a development milestone payment of $3.5 million which was accrued in the fourth quarter of 2019 and a sales-based milestone payment of $8.0 million which was accrued in the fourth quarter of 2021, and accrued another development milestone of $4.0 million. The Company may be required to pay an additional aggregate amount of up to $28.0 million in development, regulatory, and sales-based milestones as well as certain royalties at tiered percentages rates ranging from mid- to high-teens on annual net sales of the licensed products in the licensed territory. License and collaboration agreement with Paratek Bermuda Ltd. (“Paratek”) In April 2017, the Company entered into a license and collaboration agreement with Paratek, pursuant to which the Company obtained both an exclusive license under certain patents and know-how of Paratek and an exclusive sub-license under certain intellectual property that Paratek licensed from Tufts University to develop, manufacture, and commercialize products containing omadacycline (ZL-2401) as an active ingredient in Greater China in the field of all human therapeutic and preventative uses other than biodefense. Under the terms of the agreement, in the first quarter of 2022, the Company made a milestone payment of $6.0 million which was accrued in the fourth quarter of 2021 related to the regulatory approval of omadacycline for the treatment of adults with Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia in mainland China in December 2021. The Company may be required to pay an additional aggregate amount of up to $40.5 million in development and sales-based milestones as well as certain royalties at tiered percentages rates ranging from low- to mid-teens on annual net sales of licensed products in the licensed territory. Collaboration and license agreement with argenx BV (“argenx”) In January 2021, the Company entered into a collaboration and license agreement with argenx pursuant to which the Company received an exclusive license to develop and commercialize products containing argenx’s proprietary antibody fragment, known as efgartigimod, in Greater China. Pursuant to the collaboration and license agreement, a share issuance agreement was entered into between the Company and argenx. As the upfront payment to argenx, the Company issued 5,681,820 ordinary shares of the Company with a par value of $0.000006 per share to argenx on the closing date of January 13, 2021. In determining the fair value of the ordinary shares at closing, the Company considered the closing price of the ordinary shares on the closing date and included a lack of marketability discount because the shares were subject to certain restrictions. The fair value of the shares on the closing date was determined to be $62.3 million in the aggregate. In addition, the Company made a non-creditable, non-refundable development cost-sharing payment of $75.0 million to argenx during the first quarter of 2021. Under the terms of the agreement, the Company made a milestone payment of $25.0 million in the first quarter of 2022 which was accrued in the fourth quarter of 2021 related to the first regulatory approval for the licensed product by the U.S. Food and Drug Administration (“FDA”) in December 2021. The Company may be required to pay certain royalties at tiered percentages rates ranging from mid-teen to low-twenties on annual net sales of licensed products in the licensed territory. Collaboration and license agreement with Mirati Therapeutics, Inc. (“Mirati”) In May 2021, the Company entered into a collaboration and license agreement with Mirati pursuant to which the Company obtained the right to research, develop, manufacture, and exclusively commercialize adagrasib in Greater China. Under the terms of the agreement, the Company made an upfront payment of $65.0 million to Mirati in the second quarter of 2021. In the third quarter of 2022, the Company made a development milestone payment of $5.0 million which was accrued in the second quarter of 2022 and accrued a development milestone payment of $5.0 million. The Company may be required to pay an additional aggregate amount of up to $263.0 million in development, regulatory, and sales-based milestone payments as well as certain royalties at tiered percentage rates ranging from high-teens to low-twenties on annual net sales of adagrasib in Greater China. License agreement with Karuna Therapeutics, Inc. (“Karuna”) In November 2021, the Company entered into a license agreement with Karuna for the development, manufacturing, and commercialization of KarXT (xanomeline-trospium) in Greater China. Under the terms of the agreement, the Company made an upfront payment of $35.0 million to Karuna in the fourth quarter of 2021. The Company also made a development milestone payment of $5.0 million in the third quarter of 2022 which was accrued in the second quarter of 2022. The Company may be required to pay an additional aggregate amount of up to $147.0 million in development, regulatory, and sales-based milestone payments as well as certain royalties at tiered percentage rates ranging from low- to high-teens on annual net sales of licensed products in Greater China. Collaboration and license agreement with Seagen Inc. (“Seagen”) In September 2022, the Company entered into a collaboration and license agreement with Seagen, pursuant to which the Company and Seagen agreed to collaboratively develop and commercialize TIVDAK ® (tisotumab vedotin). Under the agreement, the Company obtained an exclusive license to develop and commercialize TIVDAK in Greater China. Under the terms of the agreement, the Company accrued an upfront payment of $30.0 million in the third quarter of 2022. The Company may be required to pay an additional aggregate amount of up to $263.0 million in development, regulatory, and sales-based milestone payments as well as certain royalties at tiered percentage rates ranging from mid-teens to low-twenties on annual net sales of licensed products in Greater China, subject to reduction under specified circumstances. The agreement will remain in effect, unless earlier terminated, until the expiration of the last-to-expire royalty term for the last licensed product. The agreement contains customary provisions for termination by either party, including in the event of a material breach by the other party that remains uncured, by the Company for convenience, for certain bankruptcy events, and by Seagen upon a challenge of the licensed patent rights.

Restricted net assets

Restricted net assets	9 Months Ended
Restricted net assets	Sep. 30, 2022
Restricted net assets
Restricted net assets	Restricted net assets The Company’s ability to pay dividends may depend on the Company receiving distributions of funds from its Chinese subsidiaries. Relevant Chinese laws and regulations permit payments of dividends by the Company’s Chinese subsidiaries only out of its retained earnings, if any, as determined in accordance with Chinese accounting standards and regulations. The results of operations reflected in the unaudited condensed consolidated financial statements prepared in accordance with U.S. GAAP differ from those reflected in the statutory financial statements of the Company’s Chinese subsidiaries. In accordance with the Company Law of the People’s Republic of China, a domestic enterprise is required to provide statutory reserves of at least 10% of its annual after-tax profit until such reserve has reached 50% of its respective registered capital based on the enterprise’s Chinese statutory accounts. A domestic enterprise may provide discretionary surplus reserve, at the discretion of the Board of Directors, from the profits determined in accordance with the enterprise’s Chinese statutory accounts. The aforementioned reserves can only be used for specific purposes and are not distributable as cash dividends. The Company’s Chinese subsidiaries were established as domestic enterprises and therefore are subject to the above-mentioned restrictions on distributable profits. During the three and nine months ended September 30, 2022 and 2021, no appropriation to statutory reserves was made because the Chinese subsidiaries had substantial losses during such periods. As a result of these Chinese laws and regulations, subject to the limits discussed above that require annual appropriations of 10% of after-tax profit to be set aside, prior to payment of dividends, as general reserve fund, the Company’s Chinese subsidiaries are restricted in their ability to transfer a portion of their net assets to the Company.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies (a) Purchase commitments As of September 30, 2022, the Company’s commitments related to purchase of property and equipment contracted but not yet reflected in the unaudited condensed consolidated financial statements were $13.8 million and were expected to be incurred within one year. (b) Contingencies

Subsequent Events

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date financial statements were issued. The Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.

Basis of presentation and con_2

Basis of presentation and consolidation and significant accounting policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of presentation	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”), and applicable rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”), regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in the Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 1, 2022 (the “2021 Annual Report”). The December 31, 2021 condensed consolidated balance sheet data included in this Quarterly Report on Form 10-Q were derived from the audited financial statements included in the 2021 Annual Report. The accompanying condensed consolidated financial statements reflect all normal recurring adjustments that are necessary to present fairly the results for the interim periods presented. Interim results are not necessarily indicative of the results for the year ending December 31, 2022. Effective as of March 30, 2022, the Company subdivided each of its issued and unissued ordinary shares into ten ordinary shares (the “Share Subdivision”). Following the Share Subdivision, the Company’s authorized share capital became $30,000 divided into 5,000,000,000 shares with a par value of $0.000006 per share. The numbers of issued and unissued ordinary shares and per share data as disclosed elsewhere in these unaudited condensed consolidated financial statements and notes thereto are presented on a basis after taking into account the effects of the Share Subdivision and have been retrospectively adjusted, where applicable. In connection with the Share Subdivision, the conversion ratio of our ADSs to ordinary shares changed from one ADS to one ordinary share to a new ratio of one ADS to ten ordinary shares (the “ADS Ratio Change”). The Share Subdivision and ADS Ratio Change did not result in any change to the number of outstanding ADSs of the Company. A reclassification has been made within the condensed consolidated statement of cash flow for the nine months ended September 30, 2021 to conform to the current period presentation. The Company reclassified $2.8 million from other current liabilities into foreign currency remeasurement loss. The net cash used in operating activities did not change as a result of the reclassification.
Principles of consolidation	The unaudited condensed consolidated financial statements include the financial statements of the Company and its subsidiaries. All intercompany transactions and balances among the Company and its subsidiaries are eliminated upon consolidation.
Use of estimates	The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Areas where management uses subjective judgment include, but are not limited to, estimating the useful lives of long-lived assets, estimating the current expected credit losses for financial assets, and assessing the impairment of long-lived assets, discount rate of operating lease liabilities, accrual of rebates, allocation of research and development expenses to the appropriate financial reporting period based on the progress of the research and development projects, share-based compensation expenses, recoverability of deferred tax assets, and a lack of marketability discount of the ordinary shares issued in connection with license and collaboration arrangements (Note 12). Management bases its estimates on historical experience and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from these estimates.
Fair value measurements	Financial instruments of the Company primarily include cash, cash equivalents and restricted cash, short-term investments, accounts receivable, notes receivable, prepayments and other current assets, accounts payable, and other current liabilities. As of September 30, 2022 and December 31, 2021, the carrying values of cash and cash equivalents, short-term investments, accounts receivable, notes receivable, prepayments and other current assets, accounts payable, and other current liabilities approximated their fair values due to the short-term maturity of these instruments, and the carrying value of restricted cash approximated its fair value based on the nature of the assessment of the ability to recover these amounts.
Recent accounting pronouncements	In November 2021, the FASB issued ASU2021-10, Government Assistance (Topic 832) — Disclosures by Business Entities about Government Assistance. The amendments in this ASU require disclosures about transactions with a government that have been accounted for by analogizing to a grant or contribution accounting model to increase transparency about (1) the types of transactions, (2) the accounting for the transactions, and (3) the effect of the transactions on an entity’s financial statements. The amendments in this ASU are effective for all entities within their scope for financial statements issued for annual periods beginning after December 15, 2021. The Company adopted this standard as of January 1, 2022. There was no material impact on the Company’s financial position or results of operations upon the adoption.
Significant accounting policies	For a more complete discussion of the Company’s significant accounting policies, the unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the 2021 Annual Report.

Basis of presentation and con_3

Basis of presentation and consolidation and significant accounting policies (Tables)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Schedule of assets and liabilities that are measured at fair value on a recurring basis	As of September 30, 2022 and December 31, 2021, information about inputs into the fair value measurement of the Company’s assets that are measured at a fair value on a recurring basis in periods subsequent to their initial recognition is as follows (in thousands): Description Fair Value as of Fair Value Measurement at Reporting Date Using Quoted Prices in Active Markets for Identical Assets (Level 1) US$ Equity Investments with Readily Determinable Fair Value 3,316 3,316 Description Fair Value as of Fair Value Measurement at Reporting Date Using Quoted Prices in Active Markets for Identical Assets (Level 1) US$ Equity Investments with Readily Determinable Fair Value 15,383 15,383

Cash and cash equivalents (Tabl

Cash and cash equivalents (Tables)	9 Months Ended
Cash and cash equivalents (Tables)	Sep. 30, 2022
Cash and Cash Equivalents [Abstract]
Schedule of cash and cash equivalents	The following table presents the Company’s cash and cash equivalents as of September 30, 2022 and December 31, 2021 (in thousands): September 30, 2022 December 31, 2021 $ $ Cash at bank and in hand 818,407 663,472 Cash equivalents (i) 301,069 300,628 1,119,476 964,100 Denominated in: US$ 1,072,376 932,888 RMB (ii) 41,138 23,791 Hong Kong dollar (“HK$”) 5,035 6,674 Australian dollar (“A$”) 579 475 Taiwan dollar (“TW$”) 348 272 1,119,476 964,100 (i) Cash equivalents represent short-term and highly liquid investments in a money market fund.

Inventories, net (Tables)

Inventories, net (Tables)	9 Months Ended
Inventories, net (Tables)	Sep. 30, 2022
Inventory Disclosure [Abstract]
Schedule of inventories, net	The following table presents the Company’s inventories, net, as of September 30, 2022 and December 31, 2021 (in thousands): September 30, 2022 December 31, 2021 $ $ Finished goods 8,703 5,632 Raw materials 20,397 13,231 Work in Progress 31 88 Inventories, net 29,131 18,951

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	9 Months Ended
Property and Equipment, net (Tables)	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Schedule of property and equipment, net	The following table presents the components of the Company’s property and equipment, net as of September 30, 2022 and December 31, 2021 (in thousands): September 30, 2022 December 31, 2021 $ $ Office equipment 818 836 Electronic equipment 6,744 5,036 Vehicle 198 220 Laboratory equipment 18,673 17,069 Manufacturing equipment 14,366 14,600 Leasehold improvements 10,160 10,432 Construction in progress 19,882 11,334 70,841 59,527 Less: accumulated depreciation (20,313) (16,425) Property and equipment, net 50,528 43,102

Revenue (Tables)

Revenue (Tables)	9 Months Ended
Revenue (Tables)	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
Schedule of net product sales	The table below presents the Company’s net product sales for the three and nine months ended September 30, 2022 and 2021 (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 $ $ $ $ Product revenue - gross 60,446 47,555 168,095 135,490 Less: Rebate and sales return (3,483) (4,452) (17,462) (35,349) Product revenue - net 56,963 43,103 150,633 100,141
Schedule of disaggregation of net revenue	The following table presents net revenue by product for the three and nine months ended September 30, 2022 and 2021 (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 $ $ $ $ ZEJULA 39,214 28,162 102,863 64,134 Optune 10,662 10,653 35,051 27,318 QINLOCK 5,541 4,288 9,123 8,689 NUZYRA 1,546 — 3,596 — Product revenue - net 56,963 43,103 150,633 100,141

Other current liabilities (Tabl

Other current liabilities (Tables)	9 Months Ended
Other current liabilities (Tables)	Sep. 30, 2022
Other Liabilities Disclosure [Abstract]
Schedule of other current liabilities	The following table presents the Company’s other current liabilities as of September 30, 2022 and December 31, 2021 (in thousands): September 30, December 31, $ $ Payroll 25,208 25,685 Accrued rebate to distributors 8,843 15,001 Tax payables 10,405 8,817 Accrued professional service fee 5,927 4,319 Other (i) 4,839 4,421 Payables for purchase of property and equipment 3,234 2,568 Total 58,456 60,811

Loss per share (Tables)

Loss per share (Tables)	9 Months Ended
Loss per share (Tables)	Sep. 30, 2022
Earnings Per Share [Abstract]
Schedule of basic and diluted net loss per share	The following table presents the computation of the basic and diluted net loss per share for the three and nine months ended September 30, 2022 and 2021 (in thousands, except share and per share data): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 $ $ $ $ Numerator: Net loss attributable to ordinary shareholders (161,190) (96,412) (381,517) (492,646) Denominator: Weighted average number of ordinary shares - basic and diluted 959,085,960 950,354,320 957,439,910 921,748,380 Net loss per share - basic and diluted (0.17) (0.10) (0.40) (0.53)
Schedule of anti-dilutive shares excluded from the calculation of diluted loss per share	As a result of the Company’s net loss for the three and nine months ended September 30, 2022 and 2021, share options and non-vested restricted shares outstanding in the respective periods were excluded from the calculation of diluted loss per share as their inclusion would have been anti-dilutive. September 30, September 30, Share options 90,511,530 81,801,570 Non-vested restricted shares 34,103,830 6,366,190

Share-based compensation (Table

Share-based compensation (Tables)	9 Months Ended
Share-based compensation (Tables)	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of stock-based compensation expense	Stock-based compensation expense has been reported in the Company’s condensed consolidated statements of operations and comprehensive loss as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 $ $ $ $ Selling, general and administrative 11,298 6,147 27,221 16,579 Research and development 7,809 4,409 18,521 11,527 Total 19,107 10,556 45,742 28,106

Basis of presentation and con_4

Basis of presentation and consolidation and significant accounting policies - Additional Information (Details)			9 Months Ended
	Mar. 30, 2022 USD ($) $ / shares shares	Mar. 29, 2022	Sep. 30, 2022 USD ($) $ / shares shares	Sep. 30, 2021 USD ($)	Dec. 31, 2021 $ / shares shares
Accounting Policies [Abstract]
Share Subdivision ratio	10
Ordinary shares, authorized share capital	$ 30,000
Ordinary shares, shares authorized (in shares) \| shares	5,000,000,000		5,000,000,000		5,000,000,000
Ordinary shares, par value (in dollars per share) \| $ / shares	$ 0.000006		$ 0.000006		$ 0.000006
ADS to ordinary shares conversion ratio	10	1
Reclassification [Line Items]
Foreign currency remeasurement loss			$ 73,052,000	$ 2,838,000
Other current liabilities			$ (1,628,000)	(20,591,000)
Reclassification adjustment
Reclassification [Line Items]
Foreign currency remeasurement loss				2,800,000
Other current liabilities				$ 2,800,000

Basis of presentation and con_5

Basis of presentation and consolidation and significant accounting policies - Summary of Assets and Liabilities that are Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Investments with Readily Determinable Fair Value	$ 3,316	$ 15,383
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Investments with Readily Determinable Fair Value	$ 3,316	$ 15,383

Cash and cash equivalents (Deta

Cash and cash equivalents (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021
Cash And Cash Equivalents [Line Items]
Cash at bank and in hand	$ 818,407	$ 663,472
Cash equivalents	301,069	300,628
Cash and cash equivalents	1,119,476	964,100	$ 1,398,498
US$
Cash And Cash Equivalents [Line Items]
Cash and cash equivalents	1,072,376	932,888
RMB
Cash And Cash Equivalents [Line Items]
Cash and cash equivalents	41,138	23,791
Hong Kong dollar (“HK$”)
Cash And Cash Equivalents [Line Items]
Cash and cash equivalents	5,035	6,674
Australian dollar (“A$”)
Cash And Cash Equivalents [Line Items]
Cash and cash equivalents	579	475
Taiwan dollar (“TW$”)
Cash And Cash Equivalents [Line Items]
Cash and cash equivalents	$ 348	$ 272

Inventories, net - Additional I

Inventories, net - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Inventory Disclosure [Abstract]
Net inventory balance	$ 29,131		$ 29,131		$ 18,951
Inventory write-down	$ 300	$ 100	$ 500	$ 400

Inventories, net - Summary of i

Inventories, net - Summary of inventories, net (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Finished goods	$ 8,703	$ 5,632
Raw materials	20,397	13,231
Work in Progress	31	88
Inventories, net	$ 29,131	$ 18,951

Property and Equipment, net - S

Property and Equipment, net - Summary of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Property Plant And Equipment
Property and equipment, gross	$ 70,841	$ 59,527
Less: accumulated depreciation	(20,313)	(16,425)
Property and equipment, net	50,528	43,102
Office equipment
Property Plant And Equipment
Property and equipment, gross	818	836
Electronic equipment
Property Plant And Equipment
Property and equipment, gross	6,744	5,036
Vehicle
Property Plant And Equipment
Property and equipment, gross	198	220
Laboratory equipment
Property Plant And Equipment
Property and equipment, gross	18,673	17,069
Manufacturing equipment
Property Plant And Equipment
Property and equipment, gross	14,366	14,600
Leasehold improvements
Property Plant And Equipment
Property and equipment, gross	10,160	10,432
Construction in progress
Property Plant And Equipment
Property and equipment, gross	$ 19,882	$ 11,334

Property and Equipment, net - A

Property and Equipment, net - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
Depreciation expenses	$ 2.1	$ 1.5	$ 5.7	$ 4.3

Revenue - Summary of Net Produc

Revenue - Summary of Net Product Sales (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue from Contract with Customer [Abstract]
Product revenue - gross	$ 60,446	$ 47,555	$ 168,095	$ 135,490
Less: Rebate and sales return	(3,483)	(4,452)	(17,462)	(35,349)
Product revenue - net	$ 56,963	$ 43,103	$ 150,633	$ 100,141

Revenue - Additional Informatio

Revenue - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
Revenue - Additional Information (Details) - USD ($)	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue from Contract with Customer [Abstract]
Collaboration revenue	$ 577,000	$ 0	$ 1,806,000	$ 0

Revenue - Disaggregation of Net

Revenue - Disaggregation of Net Revenue by Product (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Disaggregation of Revenue [Line Items]
Product revenue - net	$ 56,963	$ 43,103	$ 150,633	$ 100,141
ZEJULA
Disaggregation of Revenue [Line Items]
Product revenue - net	39,214	28,162	102,863	64,134
Optune
Disaggregation of Revenue [Line Items]
Product revenue - net	10,662	10,653	35,051	27,318
QINLOCK
Disaggregation of Revenue [Line Items]
Product revenue - net	5,541	4,288	9,123	8,689
NUZYRA
Disaggregation of Revenue [Line Items]
Product revenue - net	$ 1,546	$ 0	$ 3,596	$ 0

Income tax (Details)

Income tax (Details) - USD ($)	3 Months Ended		9 Months Ended
Income tax (Details) - USD ($)	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Provision for income taxes	$ 0	$ 0	$ 0	$ 0
Unrecognized tax benefits	0		0		$ 0
Unrecognized tax benefits, interest and penalties	$ 0	$ 0	$ 0	$ 0

Other current liabilities (Deta

Other current liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Other Liabilities Disclosure [Abstract]
Payroll	$ 25,208	$ 25,685
Accrued rebate to distributors	8,843	15,001
Tax payables	10,405	8,817
Accrued professional service fee	5,927	4,319
Other	4,839	4,421
Payables for purchase of property and equipment	3,234	2,568
Total	$ 58,456	$ 60,811

Loss per share - Computation of

Loss per share - Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Numerator:
Net loss attributable to ordinary shareholders - basic	$ (161,190)	$ (96,412)	$ (381,517)	$ (492,646)
Net loss attributable to ordinary shareholders - diluted	$ (161,190)	$ (96,412)	$ (381,517)	$ (492,646)
Denominator:
Weighted average number of ordinary shares - basic (in shares)	959,085,960	950,354,320	957,439,910	921,748,380
Weighted average number of ordinary shares - diluted (in shares)	959,085,960	950,354,320	957,439,910	921,748,380
Net loss per share - basic (in dollars per share)	$ (0.17)	$ (0.10)	$ (0.40)	$ (0.53)
Net loss per share - diluted (in dollars per share)	$ (0.17)	$ (0.10)	$ (0.40)	$ (0.53)

Loss per share - Summary of Ant

Loss per share - Summary of Anti-Dilutive Shares Excluded from Calculation of Diluted Loss Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Share options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive shares excluded from calculation of diluted loss per share	90,511,530	81,801,570
Non-vested restricted shares
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive shares excluded from calculation of diluted loss per share	34,103,830	6,366,190

Related party transactions (Det

Related party transactions (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Research and development \| Limited Liability Company
Related Party Transaction [Line Items]
Transactions between its related party	$ 0	$ 0.1	$ 0.3	$ 0.3

Share-based compensation - Addi

Share-based compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	9 Months Ended
	Aug. 31, 2017	Sep. 30, 2022	Jun. 22, 2022	Apr. 01, 2022
Share options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized share-based compensation expense related to unvested share options granted		$ 111.9
Recognized over a weighted-average period		3 years 5 months 19 days
Non-vested restricted shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Recognized over a weighted-average period		3 years 8 months 12 days
Unrecognized share-based compensation expense related to unvested restricted shares		$ 143
2017 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Threshold annual increase to the number of ordinary shares reserved as a percentage of number of ordinary shares outstanding	4%
Shares reserved under the plan (in shares)				75,562,170
Options granted (in shares)		19,357,640
Weighted-average grant-date fair value of options granted (in dollars per share)		$ 2.84
2017 Plan \| Share options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Contractual term		10 years
Vesting period		5 years
2017 Plan \| Non-vested restricted shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Non-option awards granted (in shares)		28,320,790
2017 Plan \| Tranche one \| Share options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting percentage		20%
2017 Plan \| Tranche two \| Share options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting percentage		20%
2017 Plan \| Tranche three \| Share options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting percentage		20%
2017 Plan \| Tranche four \| Share options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting percentage		20%
2017 Plan \| Tranche five \| Share options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting percentage		20%
2017 Plan \| Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price of options granted (in dollars per share)		$ 2.95
2017 Plan \| Minimum \| Non-vested restricted shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period		4 years
2017 Plan \| Minimum \| Tranche one \| Non-vested restricted shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting percentage		20%
2017 Plan \| Minimum \| Tranche two \| Non-vested restricted shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting percentage		20%
2017 Plan \| Minimum \| Tranche three \| Non-vested restricted shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting percentage		20%
2017 Plan \| Minimum \| Tranche four \| Non-vested restricted shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting percentage		20%
2017 Plan \| Minimum \| Tranche five \| Non-vested restricted shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting percentage		20%
2017 Plan \| Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price of options granted (in dollars per share)		$ 6.29
2017 Plan \| Maximum \| Non-vested restricted shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period		5 years
2017 Plan \| Maximum \| Tranche one \| Non-vested restricted shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting percentage		25%
2017 Plan \| Maximum \| Tranche two \| Non-vested restricted shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting percentage		25%
2017 Plan \| Maximum \| Tranche three \| Non-vested restricted shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting percentage		25%
2017 Plan \| Maximum \| Tranche four \| Non-vested restricted shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting percentage		25%
2022 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares authorized (in shares)			97,908,743

Share-based compensation - Summ

Share-based compensation - Summary of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 19,107	$ 10,556	$ 45,742	$ 28,106
Selling, general and administrative
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	11,298	6,147	27,221	16,579
Research and development
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 7,809	$ 4,409	$ 18,521	$ 11,527

License and collaboration arr_2

License and collaboration arrangements (Details) - USD ($) $ / shares in Units, $ in Millions		3 Months Ended
	Jan. 13, 2021	Sep. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Jun. 30, 2021	Mar. 31, 2021	Mar. 30, 2022
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Ordinary shares, par value (in dollars per share)		$ 0.000006		$ 0.000006			$ 0.000006
Future contingent milestone payments		$ 5,830.7
GSK
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development milestone payment		3.5
Sales-based milestone payment		8
Milestone payments accrued		4
Maximum additional milestone payments		28
Paratek
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum additional milestone payments		40.5
Milestone payment			$ 6
argenx
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment			$ 25
Issuance of ordinary shares in connection with collaboration and license arrangement (in shares)	5,681,820
Ordinary shares, par value (in dollars per share)	$ 0.000006
Upfront payments	$ 62.3
Development cost-sharing payment						$ 75
Mirati
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development milestone payment		5
Milestone payments accrued		5
Maximum additional milestone payments		263
Upfront payments					$ 65
Karuna
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development milestone payment		5
Maximum additional milestone payments		147
Upfront payments				$ 35
Seagen
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum additional milestone payments		263
Upfront payment accrued		$ 30

Restricted net assets (Details)

Restricted net assets (Details) - PRC - USD ($)	3 Months Ended		9 Months Ended
Restricted net assets (Details) - PRC - USD ($)	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Restricted net assets
Statutory reserves	$ 0	$ 0	$ 0	$ 0
Restricted amount by subsidiaries	$ 406,000,000		$ 406,000,000		$ 406,000,000

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Millions	Sep. 30, 2022 USD ($)
Property and Equipment
Loss Contingencies [Line Items]
Purchase obligation to be incurred within one year	$ 13.8